Drug profile · INN
montelukast sodium
MONTELUKAST SODIUM
montelukast sodium (MONTELUKAST SODIUM) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — montelukast sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 2
- Data quality
- 0.89
Quick answer
montelukast sodium (MONTELUKAST SODIUM) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cysteinyl leukotriene receptor 1 antagonist
Primary target: Cysteinyl leukotriene receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is montelukast sodium?
montelukast sodium (MONTELUKAST SODIUM) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for montelukast sodium?
MONTELUKAST SODIUM is a marketed brand name for montelukast sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of montelukast sodium?
montelukast sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.